Source: Eur Respir J 2015; 45: 1293-1302
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Simonneau Gérald, D’Armini Andrea M., Ghofrani Hossein-Ardeschir, Grimminger Friedrich, Hoeper Marius M., Jansa Pavel, Kim Nick H., Wang Chen, Wilkins Martin R., Fritsch Arno, Davie Neil, Colorado Pablo, Mayer Eckhard. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293-1302

Member's Comments

No comment yet.

Related content which might interest you: Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015 The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015 Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Source: Eur Respir Rev 2009; 18: 24-28 Year: 2009 A 1-year evolution of pulmonary artery pressure in the patients treated with various therapeutic methods after acute pulmonary embolism (PE). Its impact on the chronic thromboembolic pulmonary hypertension (CTEPH) development Source: Eur Respir J 2003; 22: Suppl. 45, 221s Year: 2003 Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2007; 30: 922-927 Year: 2007 Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study Source: Annual Congress 2010 - Pulmonary hypertension updates Year: 2010 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Newly diagnosed patients with chronic thromboembolic pulmonary hypertension and PASP<50 mmHg. Do they need pulmonary endarterectomy? Source: Annual Congress 2005 - News about pulmonary embolism Year: 2005 Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment Source: International Congress 2017 – PAH and CTEPH Year: 2017 Survival in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Initial results of the UK audit of chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 486s Year: 2007 Surgical treatment of chronic thromboembolic pulmonary hypertension: a single centre experience Source: Eur Respir J 2001; 18: Suppl. 33, 14s Year: 2001 Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 Long-term outcomes of pulmonary endarterectomy (PEA) for chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2007; 30: Suppl. 51, 603s Year: 2007 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Management of chronic thromboembolic pulmonary hypertension (CTEPH): A physician-based perception study Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Open label study of bosentan in chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 706s Year: 2004 Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015